Navigation Links
AtheroNova Initiates Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
Date:6/25/2013

IRVINE, Calif., June 25, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the initiation of a Phase 1 clinical trial with its lead compound, AHRO-001.  The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

"There is a significant unmet need for effective and well-tolerated agents in the treatment of both atherosclerosis and lipid modulation," said Thomas W. Gardner, Chairman and Chief Executive Officer of AtheroNova.  "Based on AHRO-001's preclinical profile, we believe it has the potential to offer patients effective treatment for these chronic conditions with an improved therapeutic profile.  We look forward to assessing AHRO-001 in human trials and are extremely pleased to have met a significant milestone with transitioning into a clinical stage company."

The Phase 1 study is a randomized, double-blind, placebo controlled study that assesses ascending doses of AHRO-001 in healthy adult volunteers.  The program advanced into Phase 1 clinical testing following extensive successful preclinical studies with AHRO-001.

"This is clearly an exciting and transformative time for us," remarked Mark K. Wedel, MD, Chief Medical Officer of AtheroNova.

About AHRO-001

AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AtheroNova has shown positive results in animal models for regression of pl
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AtheroNova Announces Milestone Filing of IND in Russian Federation
2. AtheroNova Receives Notice of Allowance for Its US Patent Application 12/024,908
3. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
4. Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
5. Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
6. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
7. Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohns Disease
8. Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
9. Acutus Medical, Inc. Initiates "First-In-Man" Clinical Study of Real-Time 3D Imaging Catheter with CT/MRI Quality
10. ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
11. Romark Laboratories Initiates Phase 3 Trial of New Influenza Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 /CNW/ - On Aug. 20, at its annual ... Medical Association (CMA) voted on and approved a delegate ... medicinal cannabis. Bedrocan Cannabis Corp., a leading Canadian licensed ... motion. The CMA is quite right to ... smoking any plant material, including medicinal cannabis. While some ...
(Date:8/22/2014)... 22, 2014 MC Medical, a subsidiary of Mitsubishi ... Columbus, OH medical device company, have formally ... and robotic visualization system in Japan . ... in Japan in the latter half ... an extensive product portfolio in endoscopic surgery market in ...
(Date:8/22/2014)... Aug. 22, 2014 Research and Markets ... and Chinese Particulate Respirators Industry Report 2014" report ... Chinese Particulate Respirators Industry Report 2014 is a professional ... global particulate respirators industry with a focus on the ... of the industry including definitions, classifications, applications and industry ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Global and Chinese Particulate Respirators Industry Report 2014 2
... Oct. 21 Sanofi-aventis announced today,that the ... (MHLW) has granted,approval for a Supplemental New ... coronary syndrome (unstable angina pectoris, non-ST elevation,myocardial ... being planned" for Plavix(R) (clopidogrel). Approximately ...
... Makes Cover of ... Molecular Cell, BUFFALO, N.Y., ... the structure,of the first mammalian GRP94 protein implicated in immune diseases such ... a,cover article in a top scientific journal -- Molecular Cell. Gewirth,s ...
Cached Medicine Technology:Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 2Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 3Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 4Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned 5First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs 2First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs 3First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs 4
(Date:8/22/2014)... Millennium Treatment Group has recently noticed an ... level of drug use among teenagers. The treatment facility aims ... and work to minimize drug abuse. , America is currently ... addiction in history. According to the National Institute of ... aged 12 or older—or 9.2 percent of the population—had used ...
(Date:8/22/2014)... Amy Norton HealthDay Reporter ... growing number of Americans on work disability chronically use ... Researchers found that between 2007 and 2011, about 44 ... were prescribed narcotic painkillers each year. And the percentage ... 2007 to 23 percent in 2011. Experts ...
(Date:8/22/2014)... Many Americans know little about how Ebola is transmitted and ... the United States, a new survey shows. About four ... be a major Ebola outbreak in the United States, and ... will get sick with the deadly virus in the next ... poll. However, those opinions don,t match reality, the Harvard ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 Natural ... Kevin Richardson to restore his own vision from legally blind ... Michaels, prompting an investigative review. , “There is a ... or contacts for everyday function, and most people just think ... to corrective eye surgery that can be pretty risky at ...
(Date:8/22/2014)... DENVER Bcl-2-like protein 11 (BIM) deletion in ... with shorter progression free survival (PFS) in epidermal ... or chemotherapy treated Asian patients. Also, BIM deletion ... patients. , The BIM protein can activate the ... pathway in cells. BIM deletion has been detected ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 3Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 4Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Deletion predicts survival in advanced non-small cell lung cancer 2
... to new environments, scientists say , FRIDAY, Dec. 14 (HealthDay ... light on skin color changes in humans. , A ... gene that,s responsible for color differences in both species. , ... have little in common, they share many similarities, noted study ...
... Bowes Program Bolstered by Celebrity Support, WASHINGTON, ... grateful for supportive cards, especially during,the holiday season. ... to the,American Red Cross for delivery to hospitalized ... and his wife, Elizabeth, heard,about the program and ...
... Illinois smokers comply with new law, CHICAGO, Dec. 14 ... taking effect January 1. Smoke Free,Illinois makes it illegal to ... $250.00., Non-smokers are thrilled to get rid of those ... furious. Further forced into exile, smokers,can,t even huddle by the ...
... yoga one step further with,a personalized yoga mat. Introduced ... lovers the option to embroider their name, friend,s,name, or ... yoga mat., (Logo: http://www.newscom.com/cgi-bin/prnh/20071214/NYF023LOGO ), ... to offer more,options when choosing a yoga mat. "I ...
... and Lejon,Boudreaux are running a minimum of a marathon ... and tons of highway,debris to get a message across., ... to:, http://www.prnewswire.com/mnr/blackaidsinstitute/31094/ , "We want 1 million African ... National HIV Testing Day," says Sacco, 26, who came ...
... , FRIDAY, Dec. 14 (HealthDay News) -- Men whose mothers, ... in the BRCA1 or BRCA2 genes may also have the ... study finds. , Most of those men are unaware ... in Philadelphia, who examined how families discuss genetic test results. ...
Cached Medicine News:Health News:Fish Give Clues to Human Skin Color Changes 2Health News:Randy Travis Participates in American Red Cross Holiday Card Program to Wounded Service Members 2Health News:Randy Travis Participates in American Red Cross Holiday Card Program to Wounded Service Members 3Health News:Smoke Free Illinois is a Positive Change 2Health News:Is Your Yoga Mat Lacking Personality? 2Health News:Photo: Two Men Raising Awareness of HIV/AIDS by Running Minimum of a Marathon a Day from San Francisco to Los Angeles 2Health News:Photo: Two Men Raising Awareness of HIV/AIDS by Running Minimum of a Marathon a Day from San Francisco to Los Angeles 3Health News:Breast Cancer Genes Also Raise Men's Risk for Malignancy 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: